Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Sélley, Eszter ^a   Kun, Szilárd ^a   Szijártó, István A ^b   Laczy, Boglárka ^a   Kovács, Tibor ^a   Fülöp, Ferenc ^c   Wittmann, István ^a   Molnár, Gergo A ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Aortic rings; Central blood pressure; Exenatide; Glucagon like peptide 1; Vasodilation

Indexed keywords

CARBON MONOXIDE; CATALASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYSTATHIONINE GAMMA LYASE; EXENDIN 4; FREE RADICAL; GLIBENCLAMIDE; GUANYLATE CYCLASE; HYDROGEN SULFIDE; INDOMETACIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; NITRIC OXIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ; PROSTAGLANDIN; PROTEIN KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; VOLTAGE GATED CALCIUM CHANNEL;

ADULT; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; ENZYME INHIBITION; IN VITRO STUDY; MALE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN ANALYSIS; RAT; SODIUM CALCIUM EXCHANGE; THORACIC AORTA; TREATMENT RESPONSE; VASODILATATION;

ANIMALS; AORTA; AORTA, THORACIC; CARBON MONOXIDE; GLUCAGON-LIKE PEPTIDE 1; HYDROGEN SULFIDE; MALE; NITRIC OXIDE; ORGAN CULTURE TECHNIQUES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION; VASODILATOR AGENTS; VENOMS;

EID: 84897569638     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-69     Document Type: Article

References (46)

1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
2. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like-peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
3. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008, 478:136-142. 10.1016/j.abb.2008.08.001, 18708025.
4. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177. 10.1016/j.regpep.2004.08.024, 15582729.
5. Richter G, Feddersen O, Wagner U, Barth P, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993, 265:L374-L381.
6. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001, 102:81-86. 10.1016/S0167-0115(01)00300-7, 11730979.
7. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasulature and increases glucose use in microvasculature and increases glucose use in muscle via nitric oxide-dependent mechanism. Diabetes 2012, 61:888-896. 10.2337/db11-1073, 3314347, 22357961.
8. Drucker DJ. The biology of incretin hormones. Cell Metab 2006, 3:153-165. 10.1016/j.cmet.2006.01.004, 16517403.
9. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003, 55:167-194. 10.1124/pr.55.1.6, 12615957.
10. Mustafa AK, Gadalla MM, Snyder SH. Signaling by gasotransmitters. Sci Signal 2009, 2(68):re2. doi:10.1126/scisignal.268re2, 2744355, 19401594.
11. Martelli A, Testai L, Breschi MC, Lawson K, McKay NG, Miceli F, Taglialatela M, Calderone V. Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacol Res 2013, 70:27-34. 10.1016/j.phrs.2012.12.005, 23287425.
12. Zavaritskaya O, Zhuravleva N, Schleifenbaum J, Gloe T, Devermann L, Kluge R, Mladenov M, Frey M, Gagov H, Fésüs G, Gollasch M, Schubert R. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. Hypertension 2013, 61:151-159. 10.1161/HYPERTENSIONAHA.112.197566, 23184384.
13. Ko EA, Han J, Jung ID, Park WS. Physiological roles of K+ channels in vascular smooth muscle cells. J Smooth Muscle Res 2008, 44:65-81. 10.1540/jsmr.44.65, 18552454.
14. Köhn C, Schleifenbaum J, Szijártó IA, Markó L, Dubrovska G, Huang Y, Gollasch M. Differential effects of cystathionine-γ-lyase-dependent vasodilatory H2S in periadventitial vasoregulation of rat and mouse aortas. PLoS One 2012, 7:e41951. 10.1371/journal.pone.0041951, 3411702, 22870268.
15. Halmai R, Szijártó IA, Fehér E, Fésüs G, Molnár GA, Brasnyó P, Fülöp F, Gollasch M, Koller A, Wittmann I. Cigarette smoke elicits relaxation of renal arteries. Eur J Clin Invest 2011, 41:195-202. 10.1111/j.1365-2362.2010.02386.x, 20955211.
16. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003, 305:800-811. 10.1124/jpet.103.049270, 12649306.
17. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011, 13:1145-1154. 10.1089/dia.2011.0050, 3202891, 21751887.
18. Xiao YF, Nikolskaya A, Jaye DA, Sigg DC. Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011, 10:6. 10.1186/1475-2840-10-6, 3037307, 21251280.
19. Iwamoto T, Kita S. Hypertension, Na+/Ca2+ exchanger, and Na+, K+-ATPase. Kidney Int 2006, 69:2148-2154. 10.1038/sj.ki.5000421, 16641927.
20. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999, 14(84):1020-1031.
21. Zakhary R, Gaine SP, Dinerman JL, Ruat M, Flavahan NA, Snyder SH. Heme oxygenase 2: endothelial and neuronal localization and role in endothelium-dependent relaxation. Proc Natl Acad Sci U S A 1996, 93:795-798. 10.1073/pnas.93.2.795, 40135, 8570637.
22. Wilkinson WJ, Kemp PJ. Carbon monoxide: emerging regulator of ion channels. J Phisiol 2011, 589:3055-3062.
23. Kimura H. Hydrogen sulfide: its production and functions. Exp Physiol 2011, 96(9):833-835.
24. Bucci M, Papapetropoulus A, Vellecco V, Zhou Z, Zaid Z, Giannogonas P, Cantalupo A, Dhayade S, Karalis KP, Wang R, Feil R, Cirino G. CGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. PLoS One 2012, 7:e53319. 10.1371/journal.pone.0053319, 3532056, 23285278.
25. Muzaffar S, Jeremy JY, Sparatore A, Del S, Angelini GD, Shukla N. H2S-donating sildenafil (ACS6) inhibits superoxide formation and gp91phox expression in arterial endothelial cells: role of protein kinases A and G. Br J Pharmacol 2008, 155:984-994. 2597257, 18846041.
26. Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol Rev 1999, 79:763-854.
27. Reews JP, Condrescu M. Ionic regulation of the cardiac-sodium calcium exchanger. Channels (Austin) 2008, 2:322-328. 10.4161/chan.2.5.6897, 18989096.
28. Zhao J, Majewski H. Endothelial nitric oxide attenuates Na+/Ca2+ exchanger-mediated vasoconstriction in rat aorta. Br J Pharmacol 2008, 154:982-990. 2465575, 18469841.
29. Hayes JS, Brunton LL, Mayer SE. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem 1980, 255:5113-5119.
30. Meves H. The action of prostaglandins on ion channels. Curr Neuropharmacol 2006, 4:41-57. 10.2174/157015906775203048, 2430679, 18615137.
31. Lee SW, Wang HZ, Zhao W, Ney P, Brink PR, Christ GJ. Prostaglandin E1 activates the large-conductance KCa channel in human corporal smooth muscle cells. Int J Impot Res 1999, 11:189-199. 10.1038/sj.ijir.3900399, 10467518.
32. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013, 19:567-575. 10.1038/nm.3128, 23542788.
33. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular cell adhesion molecule expression in ApoE-/- mouse model. Diab Vasc Dis Res 2011, 8:117-124. 10.1177/1479164111404257, 21562063.
34. Dong Z, Chai W, Wang W, Zhao L, Fu Z, Cao W, Liu Z. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitmen. Am J Physiol Endocrinol Metab 2013, 15(304):E222-E228.
35. Coletta C, Papapetropouls A, Erdelyi K, Olah G, Módis K, Panopoulos P, Asimakopoulou A, Gero D, Sharina I, Martin E, Szabo C. Hydrogen sulfide and nitric oxide mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci U S A 2012, 5(109):9161-9166.
36. Zembowicz A, Hatchett RJ, Jakubowski AM, Gryglewski RJ. Involvement of nitric oxide in the endothelium-dependent relaxation induced by hydrogen peroxide in the rabbit aorta. Br J Pharmacol 1993, 110:151-158. 2175976, 7693274.
37. Snetkov VA, Smirnov SV, Kua J, Aaronson PI, Ward JPT, Knock GA. Superoxide differentially controls pulmonary and systemic vascular tone through multiple signalling pathways. Cardiovasc Res 2011, 89:214-224. 10.1093/cvr/cvq275, 3002873, 20805095.
38. Gao YJ, Hirota S, Zhang DW, Janssen LJ, Lee RMK. Mechanisms of hydrogen-peroxide-induced biphasic response in rat mesenteric artery. Br J Pharmacol 2003, 138:1085-1092. 1573754, 12684264.
39. Cooke CL, Davidge ST. Endothelial-dependent vasodilation is reduced in mesenteric arteries from superoxide dismutase knockout mice. Cardiovasc Res 2003, 60:635-662. 10.1016/j.cardiores.2003.08.011, 14659809.
40. Ha SJ, Kim W, Woo JS, Kim JB, Kim SJ, Kim WS, Kim MK, Cheng XW, Kim KS. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol 2012, 32:474-480. 10.1161/ATVBAHA.110.222653, 22155457.
41. Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High central pulse pressure is independently associated with adverse cardiovascular outcome: the strong heart study. J Am Coll Cardiol 2009, 54:1730-1734. 10.1016/j.jacc.2009.05.070, 3164777, 19850215.
42. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 7:113. CAFE Investigators.
43. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013, 24:3.
44. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013, 12:130. 10.1186/1475-2840-12-130, 3847044, 24011363.
45. Meloni AR, DeYoung MB, Han J, Best JH, Grimm M. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol 2013, 23(12):48.
46. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64. 10.1186/1475-2840-11-64, 3434036, 22681705.